Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Communication Services Companies: AppLovin (APP) and Grupo Televisa, S.A.B. (TV)

Tipranks - Thu Aug 28, 2025

Companies in the Communication Services sector have received a lot of coverage today as analysts weigh in on AppLovin (APPResearch Report) and Grupo Televisa, S.A.B. (TVResearch Report).

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

AppLovin (APP)

In a report released yesterday, Bernie McTernan from Needham maintained a Hold rating on AppLovin. The company’s shares closed last Tuesday at $469.33, close to its 52-week high of $525.15.

According to TipRanks.com, McTernan is a 5-star analyst with an average return of 9.2% and a 53.3% success rate. McTernan covers the NA sector, focusing on stocks such as Genius Sports Limited, Fiverr International, and Zillow Group Class C. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for AppLovin with a $521.13 average price target.

See today’s best-performing stocks on TipRanks >>

Grupo Televisa, S.A.B. (TV)

In a report released today, Marcelo Santos from J.P. Morgan upgraded Grupo Televisa, S.A.B. to Buy. The company’s shares closed last Tuesday at $2.47.

According to TipRanks.com, Santos is a 4-star analyst with an average return of 9.1% and a 57.4% success rate. Santos covers the NA sector, focusing on stocks such as Millicom International Cellular SA, Telecom Argentina, and America Movil. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Grupo Televisa, S.A.B. with a $4.28 average price target.

Read More on APP:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.